What Investors Got Wrong About Myriad Genetics Before The Drop
If you had backed the bullish precision medicine story around Myriad Genetics, the recent Q2 revenue shortfall and guidance cut would have been a rude check on expectations. Holding Myriad Genetics over the past year would have meant a 21.0% loss, including dividends. If you made that decision on 30 October 2025, what did the original case around 6.0% revenue growth, margin recovery to 13.8%, and a 12.4x future P/E fail to account for in practice?
The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.
Myriad Genetics has already moved. Pinpoint other ways to investigate the theme among 34 healthcare AI stocks.
The Argument You Would Have Been Weighing Up On Myriad Genetics
The shares cost US$7.95 at the start of the period, and anyone looking at Myriad Genetics then faced two very different but reasonable stories.
The bullish narrative put Fair Value at US$14.33, anchored in 6.0% annual revenue growth, a profit margin recovery to 13.8%, and a future P/E of 12.4x as precision medicine and AI partnerships gained traction.
The more cautious view set Fair Value at US$7.31, stressing execution risk, payer pushback on tests like GeneSight, and the drag from higher interest costs on new borrowing.
What The Results Changed For Myriad Genetics
The Q2 2026 update from Myriad Genetics cut against the bullish script. Revenue fell to US$190.7 million from US$213.1 million and full year sales guidance was reduced to a midpoint of US$780 million, which leaned toward the cautious case. Net income was still a loss of US$43.2 million, so the hoped for margin recovery to 13.8% remained unproven, even though the net margin was higher than in 2025.
The lesson is simple. When a thesis leans on both revenue acceleration and margin repair, track the reported top line and net margin together each quarter and compare them with the original growth and profitability assumptions before updating any view of fair value.
What Today’s Myriad Genetics Price Already Assumes
Myriad Genetics trades at US$6.35 today, with the selected Narrative arguing that its Fair Value sits above that quote. The focus has shifted from broad precision medicine hopes to concrete oncology programs, AI enabled tests, and efficiency projects that aim to reshape the business mix.
The key assumption a buyer needs to test is whether current oncology, MRD and prenatal initiatives can translate into materially higher quality revenue despite ongoing payer friction.
"The main thing that has to go right is that Myriad Genetics converts current hereditary cancer and MRD pipeline momentum, commercial hiring, and prenatal product launches into higher quality test revenue despite ongoing payer friction and prenatal weakness."
One Narrative disagrees with today's price. → See where this Narrative says Myriad Genetics should trade
Find Your Own Contrarian Opportunity
The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.
- Company 1 - 22% below our estimate - targets hyperscale data center buildouts with a swelling backlog and no long-term debt.
- Company 2 - 46% below our estimate - expands from trackers into storage, inverters and eBOS to deepen utility-scale project roles.
- Company 3 - 37% below our estimate - folds recent acquisitions into a larger regional lender while shifting toward cheaper, stickier deposits.
Those are three of them. See the full list of 29 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com